- Home
- WWW vs OCS Comparison
WWW vs OCS Comparison
Compare WWW & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WWW | OCS |
|---|---|---|
| Founded | 1883 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | 60 |
| Industry | Shoe Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.8B |
| IPO Year | 2002 | N/A |
Fundamental Metrics
Financial Performance| Metric | WWW | OCS |
|---|---|---|
| Price | $17.66 | $11.42 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 6 |
| Target Price | $24.44 | ★ $42.00 |
| AVG Volume (30 Days) | 1.1M | ★ 1.1M |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.37% | N/A |
| EPS Growth | ★ 96.55 | N/A |
| EPS | ★ 0.24 | N/A |
| Revenue | ★ $1,874,300,000.00 | N/A |
| Revenue This Year | $6.65 | $466.06 |
| Revenue Next Year | $5.50 | $479.73 |
| P/E Ratio | $75.08 | ★ N/A |
| Revenue Growth | ★ 6.80 | N/A |
| 52 Week Low | $13.47 | $10.52 |
| 52 Week High | $32.80 | $34.48 |
Technical Indicators
Market Signals| Indicator | WWW | OCS |
|---|---|---|
| Relative Strength Index (RSI) | 57.31 | 24.41 |
| Support Level | $17.09 | $10.52 |
| Resistance Level | $17.70 | $21.82 |
| Average True Range (ATR) | 0.80 | 1.75 |
| MACD | 0.16 | -0.70 |
| Stochastic Oscillator | 65.85 | 5.06 |
Price Performance
Historical ComparisonAbout WWW Wolverine World Wide Inc.
Wolverine World Wide Inc is engaged in designing, manufacturing, sourcing, marketing, licensing, and distributing branded footwear, apparel, and accessories. The company's segment includes Active Group; Work Group; Corporate and Other. It generates maximum revenue from the Active Group segment. Active Group segment consists of Merrell footwear and apparel, Saucony footwear and apparel, Sweaty Betty activewear, and Chaco footwear.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.